The use of PET imaging in neurodegenerative diseases

In recent years, there was a paradigm shift in the diagnosis of neurodegenerative diseases, where the clinical testing is complemented by biomarker information. PET imaging with dedicated radiopharmaceuticals provides non-invasive biomarkers and co-morbidity information, which has brought a significant impact on clinical diagnosis and patient care. Imaging the human brain can provide unique information on the pathology and progression of neurodegenerative diseases like AD and PD. Imaging is also relevant for supporting preclinical and clinical trials of new therapeutic drugs.

This webinar is already ready over. Missed the live webinar or want to rewatch it?

Speakers

Dr Jacob Dubroff, PhD

MD, Associate Professor of Radiology

Hospital and University of Pennsylvania, US
Dr Pedro Rosa-Neto, PhD

MD, Professor of Neurology, Neurosurgery and Psychiatry

McGill University, Canada
Topics
- Amyloid PET Imaging: What are we waiting for?
- Tau imaging in typical and atypical Alzheimer's disease